Olsen K M, Bergman K L, Kaufman S S, Rebuck J A, Collier D S
Departments of Pharmacy Practice (Drs. Olsen, Bergman, Rebuck, and Collier) and Pediatric Gastroenterology (Dr. Kaufman), University of Nebraska Medical Center, Omaha, NE. E-mail:
Pediatr Crit Care Med. 2001 Jul;2(3):232-7. doi: 10.1097/00130478-200107000-00008.
To characterize the pharmacodynamics and pharmacokinetics of omeprazole suspension in critically ill pediatric liver/intestinal transplant patients. DESIGN: Open-label pharmacodynamic and pharmacokinetic study. SETTING: Pediatric intensive care unit of an academic medical center. PATIENTS: Eleven pediatric liver and/or intestinal transplant patients. INTERVENTIONS: Extemporaneously prepared 0.5 mg/kg omeprazole suspension every 12 hrs via nasogastric tube before sequential measurements of omeprazole serum concentration and gastric pH monitoring. Gastric pH was monitored continuously for 48 hrs and plasma omeprazole concentrations were determined upon first and multiple dosing. MEASUREMENTS AND MAIN RESULTS: Mean onset of action of omeprazole in a sodium bicarbonate vehicle was 62 +/- 82 mins (range, 2-226 mins). Subjects <4 yrs of age exhibited a more variable onset of omeprazole action (range, 3-226 mins) when compared with older subjects (onset of action, 2-40 min). Omeprazole maximum concentration and area under the concentration-time curve for the dosage interval were significantly greater upon multiple dosing when compared with the first dose. Mean baseline gastric pH in this study population was 1.0 +/- 0.8. Gastric pH remained >4.0 for 78.8% +/- 18.9% of the first dosage interval and 97.8% +/- 5.4% of multiple dosage intervals regardless of age when administered twice daily as a suspension. CONCLUSION: These results support the use of omeprazole administered twice daily as a suspension to maintain gastric pH of >4.0 and to achieve maximal pharmacodynamic effect in pediatric liver and/or intestinal transplant patients.
描述奥美拉唑混悬液在危重症小儿肝/肠移植患者中的药效学和药代动力学特征。
开放标签的药效学和药代动力学研究。
一所学术医疗中心的儿科重症监护病房。
11名小儿肝和/或肠移植患者。
在依次测量奥美拉唑血清浓度和监测胃pH值之前,通过鼻胃管每12小时临时配制0.5mg/kg奥美拉唑混悬液。连续48小时监测胃pH值,并在首次给药和多次给药后测定血浆奥美拉唑浓度。
以碳酸氢钠为溶媒的奥美拉唑平均起效时间为62±82分钟(范围为2 - 226分钟)。与年龄较大的受试者(起效时间为2 - 40分钟)相比,4岁以下的受试者奥美拉唑起效时间变化更大(范围为3 - 226分钟)。与首次给药相比,多次给药后奥美拉唑的最大浓度和给药间隔时间内的浓度-时间曲线下面积显著更高。本研究人群的平均基线胃pH值为1.0±0.8。当作为混悬液每日给药两次时,无论年龄大小,在首次给药间隔期间胃pH值>4.0的时间占78.8%±18.9%,在多次给药间隔期间占97.8%±5.4%。
这些结果支持将奥美拉唑每日两次作为混悬液给药,以维持胃pH值>4.0,并在小儿肝和/或肠移植患者中实现最大药效学效果。